Testing propranolol and etodolac around surgery for ovarian cancer
Tests two drugs, propranolol and etodolac, given around surgery in ovarian cancer patients.
Plain-language title generated from the registry record
Registry title: Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Key facts
- Where
- Ramat Gan and Tel Aviv, IsraelSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 85 years old?
Source: NCT06839144, who can take part
Where in Israel
- The Chaim Sheba Medical CenterRamat Gan, IsraelTaking people
- Tel Aviv Sourasky Medical Center (Ichilov Hospital)Tel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT06839144
- Record updated
- 11 July 2025
- Original description
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.Read full original descriptionShow less
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Inclusion: Age 20-85; ASA score 1-3 or ECOG Performance Status of 0 to 2; Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and/or tumor biopsy; Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer; Signed informed consent form; Willing and able to comply with study procedures (physically and mentally).
Exclusion: Patients treated chronically with any type of a beta-adrenergic blocker or a COX inhibitor, except use of Aspirin, which will be discontinued at least 7 days prior to surgery, and until 3 weeks post-surgery; Recent (within the last 5 years) or concurrent malignancies, with the exception of adequately treated in-situ carcinoma of the cervix or basal-cell carcinoma of the skin; Patients who are treated with immunosuppressive medications, including chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug; Patients with known allergy to one or more of the study medications, or to any medication from the non-steroidal anti-inflammatory drug group or beta-blockers family; Patients with active peptic disease; Patients with a history of CVA/TIA; Patients with significant heart failure (NYHA functional class 3 or Higher); Patients with bradycardia (heart rate of 50 or less) or second- or third-degree AV block; Patients with right-sided heart failure owing to pulmonary hypertension; Patients with Printzmetal's angina; Patients suffering from sick sinus syndrome; Patients with peripheral vascular disease; Patients with Immunodeficiency Disorders; Patients with renal failure, measured by creatinine level >1.5; Patients with significant liver dysfunction (known cirrhosis, Bilirubin level>2); Patients who participate in another interventional study; Patients currently suffering from asthma (אסתמה פעילה בלבד), or required hospital admission or change in medical treatment for asthma within the past year; Patients with chronic Digoxin treatment; Patients with significant diagnosed cardiomegaly; Patients with current (unresected) pheochromocytoma; Pregnant women.